Back to top
more

Ardelyx (ARDX)

(Delayed Data from NSDQ)

$6.86 USD

6.86
3,897,493

+0.08 (1.18%)

Updated May 31, 2024 04:00 PM ET

After-Market: $6.86 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (82 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for ARDX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

1 item in cart

View Cart/Checkout

Ardelyx, Inc. [ARDX]

Reports for Purchase

Showing records 121 - 140 ( 171 total )

Company: Ardelyx, Inc.

Industry: Medical - Drugs

Record: 121

02/22/2017

Company Report

Pages: 7

4Q/FY16, ARDX-Key Catalysts Ahead, Reiterate OUTPERFORM and as BEST IDEA for 2017

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Ardelyx, Inc.

Industry: Medical - Drugs

Record: 122

02/15/2017

Daily Note

Pages: 5

Tenapanor Meets Efficacy Endpoints in First Hyperphosphatemia Ph 3, Acceptable Safety, Reiterate OUTPERFORM rating and as Best Idea

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 10.00

Research Provided by a Third Party

Company: Ardelyx, Inc.

Industry: Medical - Drugs

Record: 123

02/10/2017

Daily Note

Pages: 5

The Week Ahead in Life Sciences: Upcoming Events for the Week of Feb 13

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 10.00

Research Provided by a Third Party

Company: Ardelyx, Inc.

Industry: Medical - Drugs

Record: 124

01/30/2017

Daily Note

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of Jan 30

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 10.00

Research Provided by a Third Party

Company: Ardelyx, Inc.

Industry: Medical - Drugs

Record: 125

01/30/2017

Daily Note

Pages: 10

Best Ideas List-Updates

Provider: WEDBUSH SECURITIES INC.

Price: 25.00

Research Provided by a Third Party

Company: Ardelyx, Inc.

Industry: Medical - Drugs

Record: 126

01/13/2017

Industry Report

Pages: 6

The Week Ahead in Life Sciences - Upcoming Events for the Week of Jan 16

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Ardelyx, Inc.

Industry: Medical - Drugs

Record: 127

01/06/2017

Daily Note

Pages: 7

Nephrologist Doctor Call Takeaways: High Unmet Need in Hyperphosphatemia, Better Patient Outcomes Possible with Tenapanor; Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Ardelyx, Inc.

Industry: Medical - Drugs

Record: 128

01/03/2017

Industry Report

Pages: 12

2017 Preview: Our Top Picks, and Key Data Readouts and Launches Up Ahead

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Ardelyx, Inc.

Industry: Medical - Drugs

Record: 129

12/21/2016

Daily Note

Pages: 8

Revised Best Ideas List for 2017

Provider: WEDBUSH SECURITIES INC.

Price: 25.00

Research Provided by a Third Party

Company: Ardelyx, Inc.

Industry: Medical - Drugs

Record: 130

12/18/2016

Industry Report

Pages: 6

The Week Ahead in Life Sciences - Upcoming Events for the Week of Dec. 19

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Ardelyx, Inc.

Industry: Medical - Drugs

Record: 131

12/15/2016

Industry Report

Pages: 31

Best Ideas List for 2017This report contains brief updates on the following: ARDX, BC, BLDR, CVA, FINL, FIS, IPG, LULU, LXRX, MASI, NRZ, PFPT, PB, PHM, QUOT, SHAK, TRVN, ZNGA. These companies are covered in more detail in separate Daily Notes and/or Company Reports.

Provider: WEDBUSH SECURITIES INC.

Analyst: LURIA G

Price: 75.00

Research Provided by a Third Party

Company: Ardelyx, Inc.

Industry: Medical - Drugs

Record: 132

12/15/2016

Industry Report

Pages: 31

Best Ideas List for 2017

Provider: WEDBUSH SECURITIES INC.

Analyst: LURIA G

Price: 75.00

Research Provided by a Third Party

Company: Ardelyx, Inc.

Industry: Medical - Drugs

Record: 133

12/15/2016

Industry Report

Pages: 31

Best Ideas List for 2017

Provider: WEDBUSH SECURITIES INC.

Analyst: LURIA G

Price: 75.00

Research Provided by a Third Party

Company: Ardelyx, Inc.

Industry: Medical - Drugs

Record: 134

12/12/2016

Daily Note

Pages: 5

Plecanatide IBS-C Data Mixed Relative to Linzess, Expecting Tenapanor to Have a Stronger Clinical Profile, Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 10.00

Research Provided by a Third Party

Company: Ardelyx, Inc.

Industry: Medical - Drugs

Record: 135

11/09/2016

Industry Report

Pages: 6

Early List of Stocks the Elections Could Impact

Provider: WEDBUSH SECURITIES INC.

Analyst: LURIA G

Price: 25.00

Research Provided by a Third Party

Company: Ardelyx, Inc.

Industry: Medical - Drugs

Record: 136

11/09/2016

Industry Report

Pages: 6

After the Election: Impact to Biotech of a Trump Presidency

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Ardelyx, Inc.

Industry: Medical - Drugs

Record: 137

11/08/2016

Company Report

Pages: 8

3Q, Multiple Late Stage Data Reads in 2017, Reiterate OP

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Ardelyx, Inc.

Industry: Medical - Drugs

Record: 138

11/04/2016

Industry Report

Pages: 6

The Week Ahead in Life Sciences - Upcoming Events for the Week of Nov 7

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Ardelyx, Inc.

Industry: Medical - Drugs

Record: 139

09/01/2016

Daily Note

Pages: 44

September and Full Year 2016 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: Ardelyx, Inc.

Industry: Medical - Drugs

Record: 140

08/09/2016

Company Report

Pages: 8

2Q, We Have High Conviction on ARDX''s Late Stage Pipeline, Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party